Michiko Ohno-Oishi , Zou Meiai , Kota Sato , Seiya Kanno , Chihiro Kawano , Makoto Ishikawa , Toru Nakazawa
{"title":"CDKN2B-AS1 基因突变的 SH-SY5Y 人类神经细胞在培养条件下很脆弱","authors":"Michiko Ohno-Oishi , Zou Meiai , Kota Sato , Seiya Kanno , Chihiro Kawano , Makoto Ishikawa , Toru Nakazawa","doi":"10.1016/j.bbrep.2024.101723","DOIUrl":null,"url":null,"abstract":"<div><p>Glaucoma is a common cause of blindness worldwide. Genetic effects are believed to contribute to the onset and progress of glaucoma, but the underlying pathological mechanisms are not fully understood. Here, we set out to introduce mutations into the <em>CDKN2B-AS1</em> gene, which is known as being the closely associated with glaucoma, in a human neuronal cell line <em>in vitro</em>. We introduced gene mutations with CRISPR/Cas9 into exons and introns into the <em>CDKN2B-AS1</em> gene. Both mutations strongly promoted neuronal cell death in normal culture conditions. RNA sequencing and pathway analysis revealed that the transcriptional factor Fos is a target molecule regulating <em>CDKN2B-AS1</em> overexpression. We demonstrated that gene mutation of <em>CDKN2B-AS1</em> is directly associated with neuronal cell vulnerability <em>in vitro.</em> Additionally, Fos, which is a downstream signaling molecule of <em>CDKN2B-AS1</em>, may be a potential source of new therapeutic targets for neuronal degeneration in diseases such as glaucoma.</p></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405580824000876/pdfft?md5=ff00cffc8b3f72e0e7949504f054f895&pid=1-s2.0-S2405580824000876-main.pdf","citationCount":"0","resultStr":"{\"title\":\"SH-SY5Y human neuronal cells with mutations of the CDKN2B-AS1 gene are vulnerable under cultured conditions\",\"authors\":\"Michiko Ohno-Oishi , Zou Meiai , Kota Sato , Seiya Kanno , Chihiro Kawano , Makoto Ishikawa , Toru Nakazawa\",\"doi\":\"10.1016/j.bbrep.2024.101723\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Glaucoma is a common cause of blindness worldwide. Genetic effects are believed to contribute to the onset and progress of glaucoma, but the underlying pathological mechanisms are not fully understood. Here, we set out to introduce mutations into the <em>CDKN2B-AS1</em> gene, which is known as being the closely associated with glaucoma, in a human neuronal cell line <em>in vitro</em>. We introduced gene mutations with CRISPR/Cas9 into exons and introns into the <em>CDKN2B-AS1</em> gene. Both mutations strongly promoted neuronal cell death in normal culture conditions. RNA sequencing and pathway analysis revealed that the transcriptional factor Fos is a target molecule regulating <em>CDKN2B-AS1</em> overexpression. We demonstrated that gene mutation of <em>CDKN2B-AS1</em> is directly associated with neuronal cell vulnerability <em>in vitro.</em> Additionally, Fos, which is a downstream signaling molecule of <em>CDKN2B-AS1</em>, may be a potential source of new therapeutic targets for neuronal degeneration in diseases such as glaucoma.</p></div>\",\"PeriodicalId\":8771,\"journal\":{\"name\":\"Biochemistry and Biophysics Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2405580824000876/pdfft?md5=ff00cffc8b3f72e0e7949504f054f895&pid=1-s2.0-S2405580824000876-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemistry and Biophysics Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405580824000876\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580824000876","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
SH-SY5Y human neuronal cells with mutations of the CDKN2B-AS1 gene are vulnerable under cultured conditions
Glaucoma is a common cause of blindness worldwide. Genetic effects are believed to contribute to the onset and progress of glaucoma, but the underlying pathological mechanisms are not fully understood. Here, we set out to introduce mutations into the CDKN2B-AS1 gene, which is known as being the closely associated with glaucoma, in a human neuronal cell line in vitro. We introduced gene mutations with CRISPR/Cas9 into exons and introns into the CDKN2B-AS1 gene. Both mutations strongly promoted neuronal cell death in normal culture conditions. RNA sequencing and pathway analysis revealed that the transcriptional factor Fos is a target molecule regulating CDKN2B-AS1 overexpression. We demonstrated that gene mutation of CDKN2B-AS1 is directly associated with neuronal cell vulnerability in vitro. Additionally, Fos, which is a downstream signaling molecule of CDKN2B-AS1, may be a potential source of new therapeutic targets for neuronal degeneration in diseases such as glaucoma.
期刊介绍:
Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.